EYLEA® (aflibercept) 8 mg
Overview
CONFIDENCE IN EYLEA® (aflibercept) 8 mg
Give your eligible patients up to 6 months in
- Mean CRT reductions in the EYLEA 8 mg 8q8/3 arm (QUASAR) were -342.5 µm 4 weeks after 1 dose and reduction was maintained through to Week 64.
- Mean CRT reductions in the EYLEA 8 mg 8q16 arm were -128 µm (PULSAR) and -127 µm (PHOTON) 4 weeks after 1 dose and reduction was maintained through Weeks 96-156.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
Prescribing information for EYLEA® (aflibercept)
VIEW THE DRYING, DURABILITY AND SAFETY DATA FOR EACH OF THE EYLEA 8 mg PIVOTAL TRIALS BELOW.
nAMD
Licenced for treatment intervals from
DMO
Licenced for treatment intervals from
RVO
Licenced for treatment intervals from
*For patients who are initiating treatment, EYLEA is administered with 1 injection per month for 3 consecutive doses. In nAMD/DMO, injection intervals may then be extended up to every 4 months based on the physician’s judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to Q24, such as with a treat-and-extend dosing regimen, while maintaining stable visual and/or anatomic outcomes. In RVO, injection intervals may then be extended based on the physician’s judgement of visual and/or anatomic outcomes. Consult the SmPC for full posology.
DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion. SmPC, Summary of Product Characteristics.
PP-EYL-GB-3129 | March 2026